Alexion is a global biopharmaceutical company whose mission is to develop and deliver life-changing treatments for patients with life-threatening and extremely rare diseases. Patients with serious and rare diseases often have very limited or no effective treatment options, and neither patients nor their families have hope. Our goal is to bring significant medical progress to underserved areas. We know that there is a large unmet medical need that drives us toward our goals and that the lives of patients depend on our daily activities.

Alexion is a global leader in the field of complement inhibition. Paroxysmal nocturnal hemoglobinuria is a severe ultra-rare life-threatening diseases (PNH) and the terminal complement inhibitor Soririsu as the only approved drug in the world first for the atypical hemolytic uremic syndrome (AHUS) ® (generic name : Eculizumab) is developed and sold. Soliris is currently approved in about 50 countries for PNH treatment and in about 40 countries for aHUS treatment.

In addition, as metabolic franchise, very innovative enzyme replacement therapy for patients with certain ultra-rare life-threatening diseases hypophosphatasia (HPP), the strain logic ® (generic name: Asuhotaze alpha) sells. Strensic is approved in Japan, US, Europe and Canada.

Alexion's work is recognized worldwide. For the medical discovery of Soliris, we received the Pri Gallian Award in the US (2008 Best Biotechnology Product) and France (2009 Best Drug for a Rare Disease). Forbes Magazine's World's Most Innovative Companies have been listed annually since 2012.